newsfilter
← Latest News
GlobeNewswire·

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch Biopartners", "Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced